Our study aims to evaluate the efficacy of intracapsular injection of Terlipressin versus Carbetocin injection on hemoglobin level in women undergoing abdominal laparoscopic myomectomy. Moreover, to evaluate their efficacy in decreasing blood loss on operative time and to describe the injection sequelae for the same population. This clinical study will be conducted in compliance with the clinical study protocol and applicable regulatory requirements.
Women aged 16-45 years
Appropriate medical status for laparoscopic surgery (largest myoma ≤15 cm)
Baseline hemoglobin ≥9 g/dl
No contra-indications to the use of glyopressin or carbitocin
Previous myomectomy
History of bleeding disorders
Concurrent anticoagulation therapy
History of Uncontrolled ischaemic heart disease
Parallel
Terlipressin
Drugintracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
intracapsular injection of Terlipressin versus Carbetocin on change blood loss in patient in laparoscopic myomectomy
measure the amount of blood loss in mm after intracapsular injection of Terlipressin versus Carbetocin versus saline as aplacebo in women undergoing laparoscopic myomectomy
1. To evaluate the efficacy of intracapsular injection of Terlipressin versus Carbetocin on hemoglobin
compare the hemoglobin level before and after operation after intracapsular injection of Terlipressin versus Carbetocin saline as aplacebo in women undergoing laparoscopic myomectomy
2. To evaluate the efficacy of intracapsular injection of Terlipressin versus Carbetocin on operative time
2\. To measure the operative time in minutes after intracapsular injection of Terlipressin versus Carbetocin versus saline as aplacebo in women undergoing laparoscopic myomectomy
Click on the lead sponsor to view all of their trials.
